MedTrace Logo

Coronary Artery Disease Screening in Patients With Chronic Kidney Disease

NCT07585695 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 283

Last updated 2026-05-14

No results posted yet for this study

Summary

Patients with chronic kidney disease (CKD) have a markedly increased cardiovascular risk, with coronary artery disease being a leading cause of morbidity and mortality. Conventional cardiovascular risk scores and non-invasive diagnostic tests have limited accuracy in this population, partly due to atypical symptoms and frequent structural heart disease. Coronary flow reserve (CFR) is a key marker of coronary microvascular dysfunction and has strong prognostic value, but its assessment is usually limited to invasive techniques. Recent advances in cadmium-zinc-telluride single-photon emission computed tomography (CZT-SPECT) allow non-invasive measurement of CFR. The EVACKD study aims to evaluate the prognostic value of CFR assessed by CZT-SPECT in patients with CKD for predicting major adverse cardiovascular events over a 2-year follow-up.

Conditions

  • Chronic Kidney Disease (CKD)
  • Coronary Artery Disease (CAD)

Sponsors & Collaborators

  • University Hospital, Grenoble

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2027-11-30
Completion
2028-01-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07585695 on ClinicalTrials.gov